stronger warnings to avoid mycophenolate (CellCept, Myfortic) during pregnancy

Please see updated information from the FDA

You'll see stronger warnings to avoid mycophenolate (CellCept, Myfortic) during pregnancy.

This is due to new evidence of a higher risk of miscarriage and birth defects in women taking mycophenolate to prevent transplant rejection.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote